Who Owns Cencora Company?

Cencora Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Cencora?

Understanding Cencora's ownership is key to grasping its market influence and strategic direction. The company, formerly AmerisourceBergen Corporation, rebranded on August 30, 2023, to reflect its global reach and expanded services.

Cencora, established in 2001, is a major force in the pharmaceutical supply chain, aiming to improve patient access to medicines globally. Its recent Cencora PESTEL Analysis highlights its operational environment.

As of August 19, 2025, Cencora's market capitalization stood at approximately $57.14 billion, with fiscal year 2024 revenues reaching $294 billion, underscoring its significant presence in the healthcare sector.

Cencora, Inc. as it is known today, did not originate from a single founder but rather from the strategic merger of AmeriSource Health Corporation and Bergen Brunswig Corporation. This significant 'merger of equals' was finalized on August 29, 2001, officially creating AmerisourceBergen Corporation.

Merger of Equals

AmeriSource Health and Bergen Brunswig merged on August 29, 2001. This combined entity became AmerisourceBergen Corporation.

Early Industry Roots

The legacy of Cencora's predecessors extends over a century. Bergen Brunswig's origins trace back to 1871, focusing on wholesale drug distribution.

Technological Advancements

Early innovations included computerized punch cards in 1947 and electronic purchase orders in 1971. These advancements streamlined pharmaceutical supply chains.

Post-Merger Leadership

David Yost, formerly CEO of AmeriSource, continued as CEO of the newly formed AmerisourceBergen. The company began trading on the NYSE as 'ABC' on August 30, 2001.

Shareholder Structure

The merger was a stock-for-stock transaction. Ownership was distributed among the former shareholders of both AmeriSource Health and Bergen Brunswig.

Initial Outstanding Shares

Following the merger, the combined entity had approximately 103 million shares outstanding. This reflects the integration of the two predecessor companies.

The historical roots of Cencora's predecessors are deep, with Bergen Brunswig's legacy beginning with Lucien Napoleon Brunswig's apprenticeship in 1871. By 1907, the Brunswig Drug Company was exclusively focused on wholesale drug distribution, identifying a critical need for a reliable supply chain to deliver medications. Early technological innovations, such as computerized punch cards for inventory tracking in 1947 and the pioneering use of computers for inventory control in 1959 by Bergen Drug Company, laid the groundwork for efficiency. By 1971, Bergen Brunswig Corporation had revolutionized the industry with electronic transmission of purchase orders, reducing distribution time to 24 hours, a testament to their commitment to operational excellence, which is further explored in the Marketing Strategy of Cencora.

Founding and Early Ownership Dynamics

Cencora's formation as AmerisourceBergen in 2001 was a result of a merger, not a single founder. Ownership was distributed among the shareholders of the merging entities.

• AmeriSource Health Corporation and Bergen Brunswig Corporation merged to form AmerisourceBergen.
• The merger was completed on August 29, 2001, with trading commencing August 30, 2001.
• David Yost, former CEO of AmeriSource, became CEO of the new entity.
• The transaction was a stock-for-stock merger, distributing ownership to former shareholders.
• Approximately 103 million shares were outstanding at the inception of the combined company.

Cencora SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Cencora, formerly known as AmerisourceBergen, transitioned to a publicly traded entity on the NYSE in August 2001. Its market capitalization has shown significant expansion, growing from $1.54 billion in December 1998 to an estimated $57.14 billion by August 19, 2025, reflecting a compound annual growth rate of 14.48%.

The ownership of Cencora is largely concentrated among institutional investors, who collectively hold approximately 97.52% of the company's stock. This indicates a strong reliance on large financial institutions for the company's equity. Walgreens Boots Alliance (WBA) has historically been a significant stakeholder, having announced its intention in March 2016 to acquire a 15% stake. However, WBA has been progressively reducing its holdings, with Cencora repurchasing shares from WBA in August 2024 for about $250 million and again in May 2024 for $400 million, as part of WBA's broader divestment strategies. These transactions highlight dynamic shifts in major shareholder positions, influenced by portfolio management and strategic corporate decisions.

Understanding Cencora's Shareholder Landscape

Institutional investors are the dominant force in Cencora's ownership structure. These large entities manage significant portions of the company's stock, influencing its market performance and corporate governance.

• Institutional investors hold 97.52% of Cencora's stock.
• Key institutional holders include Vanguard Group Inc. and Blackrock, Inc.
• Walgreens Boots Alliance has been reducing its stake in the company.
• These ownership shifts reflect ongoing portfolio adjustments by major stakeholders.
• For more on the company's guiding principles, explore the Mission, Vision & Core Values of Cencora.

Cencora PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of October 1, 2024, Cencora's Board of Directors comprises thirteen members. Steven H. Collis transitioned from President and CEO to Executive Chairman, with Robert P. Mauch stepping into the President and CEO roles and joining the Board. Mark Durcan serves as the Lead Independent Director.

Cencora operates with a standard corporate governance structure, typical for publicly traded entities on the NYSE under the ticker symbol COR. The company's voting power is generally distributed on a one-share-one-vote basis. As of March 31, 2024, the aggregate market value of voting stock held by non-affiliates was $29,546,011,267. There have been no recent public reports indicating dual-class share structures or significant shifts in voting power due to activist investor campaigns, suggesting a stable ownership framework. Understanding the company's leadership and governance is key to understanding Cencora ownership.

Key Governance Aspects

Cencora's board composition has seen recent updates to enhance its leadership and strategic oversight.

• The board size increased to thirteen members as of October 1, 2024.
• Leadership transitions include the appointment of a new President and CEO.
• New independent directors have been added to bring diverse industry experience.
• The company adheres to a one-share-one-vote principle for its stock.
• For more on the company's history, see our Brief History of Cencora.

Cencora Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past three to five years, Cencora has undergone significant transformations impacting its ownership profile and strategic direction. A notable development was the company's rebranding from AmerisourceBergen to Cencora, Inc., which became effective on August 30, 2023. This change aimed to unify its global operations and better reflect its expanded role in pharmaceutical services worldwide.

Cencora has demonstrated a consistent strategy of returning capital to shareholders through share buybacks and dividends. In fiscal year 2024, the company returned $1.9 billion to shareholders, including $1.5 billion in opportunistic share repurchases. The company also announced an 8% increase in its quarterly dividend on November 6, 2024, marking its 20th consecutive annual dividend increase. This commitment to shareholder returns is a key aspect of its Cencora ownership trends.

Capital Allocation Strategy

Cencora actively manages its capital structure by returning funds to shareholders. This includes significant share repurchase programs and consistent dividend increases, reflecting a focus on enhancing shareholder value.

Strategic Acquisitions and Growth

The company has pursued strategic acquisitions to expand its market presence and service offerings. The recent acquisition of Retina Consultants of America for $4.6 billion in January 2025 exemplifies this growth-oriented approach.

Leadership and Operational Changes

Leadership transitions, such as Robert P. Mauch assuming the CEO role on October 1, 2024, are part of the company's ongoing evolution. These changes influence the strategic direction and operational execution.

Cybersecurity Incident Impact

A cyber incident disclosed in May 2024, identified in February 2024, involved data exfiltration. While efforts were made to mitigate impact, such events can influence investor confidence and operational stability.

Cencora Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔